There is an all-party group for almost every disease known to man, with the possible exception of rigor mortis. If patients and campaigners are to have confidence in clinical decision makers, there will have to be profound changes. At the moment, people lobby their MPs, who are uniquely unqualified to make these decisions. May I suggest to my hon. Friend that one of the changes might need to involve a thorough review of the framework and guidance under which the National Institute for Health and Care Excellence operates?
Breast Cancer Drugs
Proceeding contribution from
Desmond Swayne
(Conservative)
in the House of Commons on Thursday, 26 January 2017.
It occurred during Backbench debate on Breast Cancer Drugs.
Type
Proceeding contribution
Reference
620 c529 
Session
2016-17
Chamber / Committee
House of Commons chamber
Librarians' tools
Timestamp
2024-08-13 12:55:39 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012652000084
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012652000084
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012652000084